Neuraxis, INC
No enriched coverage for $NRXS in the last 7 days.
No SEC Form 4 filings for $NRXS in the last 30 days.
Neuraxis Inc has announced its net sales expectations for the three months ending March 31, 2026. The company anticipates achieving approximately $1.6 million in net sales during this period. This news was reported by Reuters.
NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
CARMEL, Ind., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- NeurAxis, Inc. ( "NeurAxis" or the "Company" ) ( NYSE:NRXS ) , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for ...
